Home › Chronic Kidney Disease › Ohio
Chronic Kidney Disease clinical trials in Ohio
15 studies for Chronic Kidney Disease are looking for participants at sites in Ohio.
Cities in Ohio
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
- Investigator Site #20, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07268638A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Velocity Clinical Research, Cincinnati, Springdale, Cincinnati
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07783802A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
- Research Site, Canton
- Research Site, Cincinnati
- Research Site, Cincinnati
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06742723A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
- Research Site, Cincinnati
- Research Site, Cincinnati
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Sep 24, 2026 · NCT07624305Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
- Cincinnati Childrens Hospital MC, Cincinnati
RecruitingPhase 3
Ages 2 to 18 · All sexes · Updated Sep 21, 2026 · NCT07498335A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 16, 2026 · NCT07107945A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
- Research Site, Cincinnati
- Research Site, Maumee
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07753993Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
- Cleveland Clinic, Cleveland
RecruitingObservational study
Ages 18 to 65 · All sexes · Updated Jul 8, 2026 · NCT06694558BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Jul 2, 2026 · NCT06741072Ferric Citrate and Chronic Kidney Disease in Children
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's, Columbus
RecruitingPhase 2
Ages 6 to 18 · All sexes · Updated Apr 17, 2026 · NCT04741646A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- Akron Nephrology Associates, Inc., Akron
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Apr 17, 2026 · NCT03619850Kidney Precision Medicine Project
- Cleveland Clinic, Cleveland
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT04334707A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
- Cleveland Clinic Foundation, Cleveland
RecruitingPhase 3
Ages 0 to 18 · All sexes · Updated Feb 27, 2026 · NCT03633708Transformative Research in Diabetic Nephropathy
- Ohio State University, Columbus
RecruitingObservational study
Ages 18 to 100 · All sexes · Updated Feb 27, 2026 · NCT02986984A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
- US Renal Care - Alexis, Toledo
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Jan 29, 2026 · NCT06933472From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.